ABX196 is Abivax's second compound in clinical development after lead drug-candidate ABX464

ABX196 was well tolerated and demonstrated promising signals of clinical benefit in heavily pretreated hepatocellular cancer patients

ABX196 phase 1/2 study results were selected for a presentation at the 2022 ASCO GI Cancers Symposium

Detailed data of the abstract submitted at the ASCO GI Cancers Symposium will be released as of January 18, 2022, in accordance with the official ASCO embargo policy